Pre-approval Information Exchange Act of 2022
Latest action · Mar 10, 2022 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 9, 2022
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Pre-approval Information Exchange Act of 2022
This bill specifies that economic, scientific, or other product support information that is exchanged between drug manufacturers and health care entities (e.g., pharmacy benefit managers) about drug products before regulatory approval is not considered to be misbranding or prohibited premarket promotion if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.
Cosponsors 1
Members who signed on, in the order they did. All signed on Mar 30, 2022.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-VA | H. Morgan Griffith | Mar 30, 2022 |
Actions 3
Everything that happened, newest first.
- Mar 10, 2022Referred to the Subcommittee on Health.
- Mar 9, 2022Introduced in House
- Mar 9, 2022Referred to the House Committee on Energy and Commerce.
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Mar 9, 2022Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.